Evidence shows that older patients can safely obtain the same treatment benefits as younger patients when they receive what type of regimens?

• A. Suboptimal dosing
• B. Full-dose standard chemotherapy regimens
• C. Shortened treatment cycles
• D. Experimental regimens

Answer: (B)

Maintaining dose intensity by delivering full-dose, standard chemotherapy regimens is the idea here. When older patients are carefully selected for fitness and receive good supportive care, they can tolerably undergo standard dosing and schedule and achieve benefits similar to younger patients—because the total amount of drug delivered over time drives tumor control. Reducing the dose or shortening cycles lowers the overall exposure to chemotherapy, which often leads to lower response rates and potentially shorter survival, even if short-term toxicity seems less. While assessment of organ function and comorbidities is important, age alone should not steer treatment away from standard-dose regimens if the patient can tolerate them with appropriate monitoring and supportive measures. Experimental regimens, though valuable in research, haven’t shown the same proven benefit in broad practice.